KDUS

 
Common Stock SEC Reporting - Current
OTCQB
Verified Company Profile 12/08/2016
Contact Info
  • 767 Fifth Avenue
  • New York, NY 10153

Business Description


 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Dec 31, 2016 10-K
CIK 0000911148
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 6500 - Real Estate
Incorporated In: DE, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts
Hunter C. Gary President, CEO
David Blitz Treasurer, Secretary
Company Directors
Jack Wasserman Chairman
Hunter C. Gary
Peter Liebert
Tara Shucts
Service Providers
Accounting/Auditing Firm
Baker Tilly Virchow Krause
One Penn Plaza
Suite 3000
New York, NY, 10119
United States
 
Grant Thornton
 
Securities Counsel
Morrison Cohen LLP
909 Third Avenue
New York, NY, 10022-4784
United States
 
Investor Relations Firm

Not Available
Company History
  • Formerly=Cadus Pharmaceutical Corp. until 7-03
KDUS Security Details
Share Structure
Market Value1 $27,602,484 a/o Apr 28, 2017
Authorized Shares 35,000,000 a/o Dec 07, 2016
Outstanding Shares 26,288,080 a/o Mar 31, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value 0.01
Shareholders
Shareholders of Record 46 a/o Mar 30, 2016
Short Selling Data
Short Interest 9,938 (-19.74%)
Mar 31, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security